|
|
| Zeile 4: |
Zeile 4: |
| | *'''[[Unproven ideas]]''' | | *'''[[Unproven ideas]]''' |
| | *'''[[Reviews on covid19 disease]]''' | | *'''[[Reviews on covid19 disease]]''' |
| − | {{tp|p=32183901|t=2020. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review |pdf=|usr=}}
| |
| − | {{tp|p=32292686|t=ä. Coronavirus: Update Related to the Current Outbreak of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32072569|t=ä. 2019 Novel coronavirus: where we are and what we know |pdf=|usr=}}
| |
| − | {{tp|p=32275259|t=2020. SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview|pdf=|usr=}}
| |
| − | {{tp|p=32275257|t=2020. Clinical manifestation, diagnosis, prevention and control of SARS-CoV-2 (COVID-19) during the outbreak period |pdf=|usr=}}
| |
| − | {{tp|p=32234465|t=ä. Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human respiratory disease: detection, mechanisms and treatment |pdf=|usr=}}
| |
| − | {{tp|p=32234468|t=ä. The epidemiology, diagnosis and treatment of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32201353|t=ä. A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence |pdf=|usr=}}
| |
| − | {{tp|p=32226295|t=2020. COVID-19: what has been learned and to be learned about the novel coronavirus disease |pdf=|usr=}}
| |
| − | {{tp|p=32226285|t=2020. SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat |pdf=|usr=}}
| |
| | | | |
| | *'''[[Research tools]]''' | | *'''[[Research tools]]''' |
| Zeile 22: |
Zeile 12: |
| | * | | * |
| | *'''[[Structure of covid19]]''' | | *'''[[Structure of covid19]]''' |
| − | {{tp|p=32092483|t=2020. Genetic diversity and evolution of SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32335334|t=ä. Emerging genetic diversity among clinical isolates of SARS-CoV-2: Lessons for today |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32004758|t=2020. Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event |pdf=|usr=}}
| |
| | | | |
| | *'''[[Target binding and uptake]]''' | | *'''[[Target binding and uptake]]''' |
| Zeile 45: |
Zeile 31: |
| | | | |
| | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' | | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' |
| − | {{tp|p=32325025|t=ä. COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 70: |
Zeile 55: |
| | | | |
| | *'''[[Heart]]''' | | *'''[[Heart]]''' |
| − | {{tp|p=32277408|t=ä. First case of COVID-19 complicated with fulminant myocarditis: a case report and insights |pdf=|usr=}}
| |
| − | {{tp|p=32360773|t=ä. May drug-related cardiovascular toxicities persist after hospital discharge in COVID-19 patients?|pdf=|usr=}}
| |
| − | {{tp|p=32276773|t=ä. Commentary: What is the relationship between Covid-19 and cardiovascular disease?|pdf=|usr=}}
| |
| − | {{tp|p=32291207|t=ä. Suspected myocardial injury in patients with COVID-19: Evidence from front-line clinical observation in Wuhan, China? |pdf=|usr=}}
| |
| − | {{tp|p=32276774|t=ä. SARS-CoV-2 inflames the heart The importance of awareness of myocardial injury in COVID-19 patients |pdf=|usr=}}
| |
| − | {{tp|p=32299753|t=ä. Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society |pdf=|usr=}}
| |
| | | | |
| | *'''[[Neurology, ophthalmology, orl]]''' | | *'''[[Neurology, ophthalmology, orl]]''' |
| Zeile 111: |
Zeile 90: |
| | * | | * |
| | *'''[[Diagnosis (Laboratory)]]''' | | *'''[[Diagnosis (Laboratory)]]''' |
| − | {{tp|p=32377507|t=ä. A Cautionary Tale of False-Negative Nasopharyngeal COVID-19 Testing |pdf=|usr=}}
| |
| − | {{tp|p=32242876|t=2020. Development of in vitro transcribed RNA as positive control for laboratory diagnosis of SARS-CoV-2 in India |pdf=|usr=}}
| |
| − | {{tp|p=32342674|t=2020. Glove-Wall System for Respiratory Specimen Collection and COVID-19 Mass Screening |pdf=|usr=}}
| |
| − | {{tp|p=32363011|t=2020. Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32007627|t=2020. Novel coronavirus: From discovery to clinical diagnostics |pdf=|usr=}}
| |
| − | {{tp|p=32304994|t=ä. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients |pdf=|usr=}}
| |
| − | {{tp|p=32224986|t=2020. Human Saliva: Non-Invasive Fluid for Detecting Novel Coronavirus (2019-nCoV) |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Diagnosis (Lung CT, Sonography)]]''' | | *'''[[Diagnosis (Lung CT, Sonography)]]''' |
| − | {{tp|p=32204949|t=ä. An update on CT chest findings in coronavirus disease-19 (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32362589|t=2020. Imaging findings of critically ill patients with coronavirus disease 2019 (COVID-19) pneumonia: a case series |pdf=|usr=}}
| |
| − | {{tp|p=32362588|t=2020. High-resolution computed tomography in a patient with COVID-19 with non-diagnostic serial radiographs |pdf=|usr=}}
| |
| − | {{tp|p=32362587|t=2020. Temporal changes in computed tomography of COVID-19 pneumonia with perilobular fibrosis |pdf=|usr=}}
| |
| − | {{tp|p=32255437|t=2020. Radiographic and Clinical Features of Children with 2019 Novel Coronavirus (COVID-19) Pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32319876|t=ä. Computed tomography (CT) scan challenges the result of SARS-CoV-2 nucleic acid test in a suspected COVID-19 case |pdf=|usr=}}
| |
| − | {{tp|p=32157862|t=2020. CT Manifestations of Novel Coronavirus Pneumonia: A Case Report |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Diagnosis (other modalities)]]''' | | *'''[[Diagnosis (other modalities)]]''' |
| Zeile 134: |
Zeile 98: |
| | | | |
| | *'''[[Respiration mgmt]]''' | | *'''[[Respiration mgmt]]''' |
| − | {{tp|p=32238613|t=2020. Novel Coronavirus 2019 (2019-nCoV) Infection: Part II - Respiratory Support in the Pediatric Intensive Care Unit in Resource-limited Settings |pdf=|usr=}}
| |
| − | {{tp|p=32238612|t=2020. Novel Coronavirus 2019 (2019-nCoV) Infection: Part I - Preparedness and Management in the Pediatric Intensive Care Unit in Resource-limited Settings |pdf=|usr=}}
| |
| − | {{tp|p=32192550|t=ä. The role of masks and respirator protection against SARS-CoV-2 |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Clinical guidelines and advice]]''' | | *'''[[Clinical guidelines and advice]]''' |
| − | {{tp|p=32362681|t=2020. Indian Society of Anaesthesiologists (ISA National) Advisory and Position Statement regarding COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32338347|t=ä. COVID-19 in Children: Clinical Approach and Management |pdf=|usr=}}
| |
| − | {{tp|p=32307120|t=ä. Palliative care strategies offer guidance to clinicians and comfort for COVID-19 patient and families |pdf=|usr=}}
| |
| − | {{tp|p=32358228|t=2020. The Imperative of Early Treatment for Children with COVID-19 Infection |pdf=|usr=}}
| |
| − | {{tp|p=32342676|t=2020. Interim Guidelines on Antiviral Therapy for COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32167442|t=ä. Involving antimicrobial stewardship programs in COVID-19 response efforts: All hands on deck |pdf=|usr=}}
| |
| − | {{tp|p=32218915|t=2020. National Institute for the Infectious Diseases ?L Spallanzani?, IRCCS Recommendations for COVID-19 clinical management |pdf=|usr=}}
| |
| − | {{tp|p=32275256|t=2020. Vademecum for the treatment of people with COVID-19 Edition 2 0, 13 March 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32303418|t=ä. More clinical warning indicators should be explored for monitoring COVID-19 patients condition |pdf=|usr=}}
| |
| − | {{tp|p=32156144|t=2020. Protocol for the development of a rapid advice guideline for prevention, management and care of children with 2019 novel coronavirus infection |pdf=|usr=}}
| |
| | | | |
| | *'''[[Risk and special populations]]''' | | *'''[[Risk and special populations]]''' |
| − | {{tp|p=32233816|t=2020. Novel coronavirus in a 15-day-old neonate with clinical signs of sepsis, a case report |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Case reports]]''' | | *'''[[Case reports]]''' |
| − | {{tp|p=32241316|t=ä. Case Report on Early Diagnosis of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32343659|t=2020. A Moderate Case of COVID-19 Viral Pneumonia During the SARS-CoV-2 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32160149|t=2020. Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with 2019 Novel Coronavirus Disease, United States |pdf=|usr=}}
| |
| − | {{tp|p=32170559|t=ä. Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19 in Wuhan |pdf=|usr=}}
| |
| − | {{tp|p=32221725|t=ä. Brief report of the first cured 2019-nCoV pneumonia patient in West China Hospital |pdf=|usr=}}
| |
| − | {{tp|p=32362649|t=2020. First isolation of SARS-CoV-2 from clinical samples in India |pdf=|usr=}}
| |
| − | {{tp|p=32358229|t=2020. COVID-19 in a Young Girl with Restrictive Cardiomyopathy and Chronic Lung Disease |pdf=|usr=}}
| |
| − | {{tp|p=32238024|t=2020. A case of imported COVID-19 diagnosed by PCR-positive lower respiratory specimen but with PCR-negative throat swabs |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Case series]]''' | | *'''[[Case series]]''' |
| − | {{tp|p=32212512|t=2020. Retrospective Analysis of 61 Cases of Children Died of Viral Pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32363222|t=ä. The clinical and immunological features of pediatric COVID-19 patients in China |pdf=|usr=}}
| |
| − | {{tp|p=32333027|t=ä. The COVID-19 Registry in Rhineland-Palatinate in the context of international registry activities documenting COVID-19 outcomes |pdf=|usr=}}
| |
| − | {{tp|p=32342479|t=ä. Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19) in Taizhou, Zhejiang, China |pdf=|usr=}}
| |
| − | {{tp|p=32301099|t=ä. Clinical characteristics of COVID-19 in children compared with adults in Shandong Province, China |pdf=|usr=}}
| |
| − | {{tp|p=32227274|t=ä. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients |pdf=|usr=}}
| |
| − | {{tp|p=32223012|t=2020. Sixty-eight consecutive patients assessed for COVID-19 infection: Experience from a UK Regional infectious diseases Unit |pdf=|usr=}}
| |
| − | {{tp|p=32226287|t=2020. Evaluation of SARS-CoV-2 RNA shedding in clinical specimens and clinical characteristics of 10 patients with COVID-19 in Macau |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[The morbid survivor]]''' | | *'''[[The morbid survivor]]''' |
| − | {{tp|p=32329589|t=2020. Rehabilitation management of patients with COVID-19 Lessons learned from the first experiences in China |pdf=|usr=}}
| |
| − | {{tp|p=32316718|t=2020. Systematic rapid "living" review on rehabilitation needs due to covid-19: update to march 31st 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32293817|t=2020. Rehabilitation and respiratory management in the acute and early post-acute phase "Instant paper from the field" on rehabilitation answers to the Covid-19 emergency |pdf=|usr=}}
| |
| − | {{tp|p=32217657|t=ä. Urgent need of a management plan for survivors of COVID-19 |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| Zeile 190: |
Zeile 118: |
| | | | |
| | *'''[[Candidate Compounds Covid19]]''' | | *'''[[Candidate Compounds Covid19]]''' |
| − | {{tp|p=32320825|t=ä. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status |pdf=|usr=}}
| |
| − | {{tp|p=32328406|t=ä. Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains |pdf=|usr=}}
| |
| − | {{tp|p=32335561|t=2020. Update on treatment of COVID-19: ongoing studies between promising and disappointing results |pdf=|usr=}}
| |
| − | {{tp|p=32335560|t=2020. Improving the efficacy of Chloroquine and Hydroxychloroquine against SARS-CoV-2 may require Zinc additives - A better synergy for future COVID-19 clinical trials |pdf=|usr=}}
| |
| − | {{tp|p=32342098|t=ä. Case Report of a SARS-CoV-2 Infection in a Patient With Ulcerative Colitis on Tofacitinib |pdf=|usr=}}
| |
| − | {{tp|p=32372149|t=ä. SARS-CoV-2-mediated inflammatory response in lungs: should we look at RAGE?|pdf=|usr=}}
| |
| − | {{tp|p=32352026|t=2020. Epitope based vaccine prediction for SARS-COV-2 by deploying immuno-informatics approach |pdf=|usr=}}
| |
| − | {{tp|p=32272396|t=ä. The Possible of Immunotherapy for COVID-19: a Systematic Review |pdf=|usr=}}
| |
| − | {{tp|p=32311668|t=ä. SARS-Cov-2 infection: response of human immune system and possible implications for the rapid test and treatment |pdf=|usr=}}
| |
| − | {{tp|p=32234467|t=ä. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality |pdf=|usr=}}
| |
| − | {{tp|p=32234466|t=ä. Coronavirus disease 2019 (COVID-19): current status and future perspectives |pdf=|usr=}}
| |
| − | {{tp|p=32205204|t=ä. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial |pdf=|usr=}}
| |
| − | {{tp|p=32171740|t=ä. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?|pdf=|usr=}}
| |
| − | {{tp|p=32070753|t=2020. Chloroquine for the 2019 novel coronavirus SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32278811|t=ä. Drug repositioning is an alternative for the treatment of coronavirus COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32259575|t=ä. BARICITINIB - A JANUASE KINASE INHIBITOR - NOT AN IDEAL OPTION FOR MANAGEMENT OF COVID 19 |pdf=|usr=}}
| |
| − | {{tp|p=32361028|t=ä. ?Amantadine disrupts lysosomal gene expression; a hypothesis for COVID19 treatment ? |pdf=|usr=}}
| |
| − | {{tp|p=32251732|t=ä. Perspectives: potential therapeutic options for SARS-CoV-2 patients based on feline infectious peritonitis strategies: central nervous system invasion and drug coverage |pdf=|usr=}}
| |
| − | {{tp|p=32251731|t=ä. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection |pdf=|usr=}}
| |
| − | {{tp|p=32360231|t=ä. Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking the trimerization of viral spike glycoprotein ?|pdf=|usr=}}
| |
| − | {{tp|p=32335281|t=ä. Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32305589|t=ä. Combating Devastating COVID -19 by Drug Repurposing |pdf=|usr=}}
| |
| − | {{tp|p=32305588|t=ä. Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies |pdf=|usr=}}
| |
| − | {{tp|p=32298745|t=ä. Successful treatment of plasma exchange followed by intravenous immunogloblin in a critically ill patient with 2019 novel coronavirus infection |pdf=|usr=}}
| |
| − | {{tp|p=C7152897|t=ä. Chloroquine as prophylactic agent against COVID-19?|pdf=|usr=}}
| |
| − | {{tp|p=32283177|t=ä. Coronavirus (COVID-19), First Indication of Efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 Infections |pdf=|usr=}}
| |
| − | {{tp|p=32194152|t=ä. Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine |pdf=|usr=}}
| |
| − | {{tp|p=32179150|t=ä. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?|pdf=|usr=}}
| |
| − | {{tp|p=32147516|t=ä. Arguments in favour of remdesivir for treating SARS-CoV-2 infections |pdf=|usr=}}
| |
| − | {{tp|p=32145363|t=2020. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32363157|t=2020. Chloroquine: Can it be a Novel Drug for COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32226290|t=2020. Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32226288|t=2020. Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective |pdf=|usr=}}
| |
| − | {{tp|p=32226289|t=2020. Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32300868|t=ä. Balneotherapy and human immune function in the era of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32321655|t=ä. An anti-oxidative therapy for ameliorating cardiac injuries of critically ill COVID-19-infected patients |pdf=|usr=}}
| |
| − | {{tp|p=32251768|t=2020. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Biophysics of aerosols]]'''* | + | *'''[[Biophysics of aerosols]]''' |
| | | | |
| − | *'''[[Other routes of infection]]'''* | + | *'''[[Other routes of infection]]''' |
| | | | |
| | *'''[[Passive protective equipment]]''' | | *'''[[Passive protective equipment]]''' |
| − | {{tp|p=32275260|t=2020. Protection and disinfection policies against SARS-CoV-2 (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32223072|t=2020. COVID-19: Face masks and human-to-human transmission |pdf=|usr=}}
| |
| − | {{tp|p=32246890|t=2020. Medical masks vs N95 respirators for preventing COVID-19 in healthcare workers: A systematic review and meta-analysis of randomized trials |pdf=|usr=}}
| |
| − | {{tp|p=32365891|t=2020. COVID-19 Surface Persistence: A Recent Data Summary and Its Importance for Medical and Dental Settings |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | *'''[[Running your hospital]]''' | | *'''[[Running your hospital]]''' |
| − | {{tp|p=32275254|t=2020. Videoconferences of Infectious Diseases: An educational tool that transcends borders A useful tool also for the current COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32327236|t=ä. CoViD-19 and ortho and trauma surgery: The Italian experience |pdf=|usr=}}
| |
| − | {{tp|p=32296469|t=2020. High Risk of COVID-19 Infection for Head and Neck Surgeons |pdf=|usr=}}
| |
| − | {{tp|p=32296468|t=2020. Otorhinolaryngologists and Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32226293|t=2020. The COVID-19 outbreak and psychiatric hospitals in China: managing challenges through mental health service reform |pdf=|usr=}}
| |
| − | {{tp|p=32226291|t=2020. Progression of Mental Health Services during the COVID-19 Outbreak in China |pdf=|usr=}}
| |
| − | {{tp|p=32248966|t=2020. The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease |pdf=|usr=}}
| |
| − | {{tp|p=32339543|t=ä. Centralization of the ST elevation myocardial infarction care network in the Lombardy region during the COVID-19 outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32240484|t=ä. Providing pharmacy services at cabin hospitals at the coronavirus epicenter in China |pdf=|usr=}}
| |
| − | {{tp|p=32222911|t=ä. Providing pharmacy services during the coronavirus pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32370275|t=2020. Preparedness of Frontline Doctors in Jordan Healthcare Facilities to COVID-19 Outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32182811|t=2020. Reverse Logistics Network Design for Effective Management of Medical Waste in Epidemic Outbreaks: Insights from the Coronavirus Disease 2019 (COVID-19) Outbreak in Wuhan (China) |pdf=|usr=}}
| |
| − | {{tp|p=32230995|t=2020. Quarantine Vehicle Scheduling for Transferring High-Risk Individuals in Epidemic Areas |pdf=|usr=}}
| |
| − | {{tp|p=32225019|t=2020. Strengths, Weaknesses, Opportunities and Threats (SWOT) Analysis of China?s Prevention and Control Strategy for the COVID-19 Epidemic |pdf=|usr=}}
| |
| − | {{tp|p=32366034|t=2020. COVID-19: Present and Future Challenges for Dental Practice |pdf=|usr=}}
| |
| − | {{tp|p=32235685|t=2020. COVID-19 Outbreak: An Overview on Dentistry |pdf=|usr=}}
| |
| − | {{tp|p=32371562|t=2020. Keep cystic fibrosis patients out of the hospital |pdf=|usr=}}
| |
| − | {{tp|p=32342164|t=ä. Emergency Responses to Covid-19 Outbreak: Experiences and Lessons from a General Hospital in Nanjing, China |pdf=|usr=}}
| |
| − | {{tp|p=32345858|t=2020. Anesthesiologists and the High Risk of Exposure to COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32276755|t=ä. Infection Control against COVID-19 in Departments of Radiology |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | *'''[[Mental aspects of health professionals]]''' | | *'''[[Mental aspects of health professionals]]''' |
| − | {{tp|p=32342698|t=ä. Mental health care for medical staff and affiliated healthcare workers during the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32346406|t=2020. COVID-19 pandemic and its impact on mental health of healthcare professionals |pdf=|usr=}}
| |
| − | {{tp|p=32346373|t=2020. Survey of Insomnia and Related Social Psychological Factors Among Medical Staff Involved in the 2019 Novel Coronavirus Disease Outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32351128|t=ä. COVID 19 outbreak: impact of the quarantine-induced stress on cardiovascular disease risk burden |pdf=|usr=}}
| |
| − | {{tp|p=32255436|t=2020. Challenging Times for Children With Transfusion-dependent Thalassemia Amid the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32307028|t=ä. COVID-19: The daunting experience of healthcare workers in Sardinia, Italy |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' | | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' |
| − | {{tp|p=32370116|t=2020. A Nationwide Survey of Psychological Distress among Italian People during the COVID-19 Pandemic: Immediate Psychological Responses and Associated Factors |pdf=|usr=}}
| |
| − | {{tp|p=32155789|t=2020. Immediate Psychological Responses and Associated Factors during the Initial Stage of the 2019 Coronavirus Disease (COVID-19) Epidemic among the General Population in China |pdf=|usr=}}
| |
| − | {{tp|p=32204411|t=2020. The Impact of COVID-19 Epidemic Declaration on Psychological Consequences: A Study on Active Weibo Users |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Avoiding clinical medicine in other diseases]]''' | | *'''[[Avoiding clinical medicine in other diseases]]''' |
| Zeile 285: |
Zeile 137: |
| | | | |
| | *'''[[Economic aspects of the status hygienicus]]''' | | *'''[[Economic aspects of the status hygienicus]]''' |
| − | {{tp|p=32300537|t=ä. The economic impact of the Coronavirus 2019 (Covid-2019): Implications for the mining industry |pdf=|usr=}}
| |
| − | {{tp|p=32331259|t=2020. The Food Systems in the Era of the Coronavirus (COVID-19) Pandemic Crisis |pdf=|usr=}}
| |
| − | {{tp|p=32322132|t=ä. Converting Home Spaces Into Food Gardens At the Time of Covid-19 Quarantine: All the Benefits of Plants in This Difficult and Unprecedented Period |pdf=|usr=}}
| |
| − | {{tp|p=32202260|t=2020. COVID-19: Impact on health of people & wealth of nations |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 295: |
Zeile 143: |
| | * | | * |
| | *'''[[Host, vector, one health, atmospheric aspects]]''' | | *'''[[Host, vector, one health, atmospheric aspects]]''' |
| − | {{tp|p=32275258|t=2020. Exploring the genetics, ecology of SARS-COV-2 and climatic factors as possible control strategies against COVID-19|pdf=|usr=}}
| |
| − | {{tp|p=32040190|t=2020. A qualitative study of zoonotic risk factors among rural communities in southern China |pdf=|usr=}}
| |
| − | {{tp|p=32138266|t=2020. Potential Factors Influencing Repeated SARS Outbreaks in China |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Origin of Covid19]]''' | | *'''[[Origin of Covid19]]''' |
| − | {{tp|p=32315281|t=2020. Possible Bat Origin of Severe Acute Respiratory Syndrome Coronavirus 2 |pdf=|usr=}}
| |
| − | {{tp|p=32315626|t=2020. Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32148173|t=2020. Is SARS-CoV-2 originated from laboratory? A rebuttal to the claim of formation via laboratory recombination |pdf=|usr=}}
| |
| − | {{tp|p=32102621|t=2020. No credible evidence supporting claims of the laboratory engineering of SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32056509|t=2020. HIV-1 did not contribute to the 2019-nCoV genome |pdf=|usr=}}
| |
| − | {{tp|p=32373134|t=2020. Commentary: Origin and evolution of pathogenic coronaviruses |pdf=|usr=}}
| |
| − | {{tp|p=32317409|t=2020. Detection of coronaviruses in Pteropus & Rousettus species of bats from different States of India |pdf=|usr=}}
| |
| − | {{tp|p=32009128|t=2020. History is repeating itself: Probable zoonotic spillover as the cause of the 2019 novel Coronavirus Epidemic|pdf=|usr=}}
| |
| − | {{tp|p=32226286|t=2020. Zoonotic origins of human coronaviruses |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Remission, recurrence and persistence]]''' | | *'''[[Remission, recurrence and persistence]]''' |
| Zeile 316: |
Zeile 150: |
| | | | |
| | *'''[[Epidemiology]]''' | | *'''[[Epidemiology]]''' |
| − | {{tp|p=32291244|t=ä. Travel health risk perceptions of Chinese international students in Australia ? Implications for COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32305323|t=ä. Hajj in the Time of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=C7186134|t=ä. A COVID-19 epidemic model with latency period |pdf=|usr=}}
| |
| − | {{tp|p=32346663|t=2020. A simple model for COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=C7118312|t=2020. Propagation analysis and prediction of the COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32289100|t=2020. Why is it difficult to accurately predict the COVID-19 epidemic?|pdf=|usr=}}
| |
| − | {{tp|p=32355904|t=2020. To mask or not to mask: Modeling the potential for face mask use by the general public to curtail the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32190785|t=ä. Transmission potential of the novel coronavirus (COVID-19) onboard the Diamond Princess Cruises Ship, 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32110742|t=2020. Real-time forecasts of the COVID-19 epidemic in China from February 5th to February 24th, 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32099934|t=2020. An updated estimation of the risk of transmission of the novel coronavirus (2019-nCov) |pdf=|usr=}}
| |
| − | {{tp|p=32209118|t=2020. Using the spike protein feature to predict infection risk and monitor the evolutionary dynamic of coronavirus |pdf=|usr=}}
| |
| − | {{tp|p=32111262|t=2020. A mathematical model for simulating the phase-based transmissibility of a novel coronavirus |pdf=|usr=}}
| |
| − | {{tp|p=32264957|t=2020. Fighting against the common enemy of COVID-19: a practice of building a community with a shared future for mankind |pdf=|usr=}}
| |
| − | {{tp|p=32201554|t=2020. COVID-19 R0: Magic number or conundrum?|pdf=|usr=}}
| |
| − | {{tp|p=32278147|t=2020. Mathematical model of infection kinetics and its analysis for COVID-19, SARS and MERS |pdf=|usr=}}
| |
| − | {{tp|p=32274649|t=ä. SARS-CoV-2 and Europe: timing of containment measures for outbreak control |pdf=|usr=}}
| |
| − | {{tp|p=32185635|t=ä. Successful containment of COVID-19: the WHO-Report on the COVID-19 outbreak in China |pdf=|usr=}}
| |
| − | {{tp|p=32275255|t=2020. Genomic Epidemiology and its importance in the study of the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32350571|t=ä. SARS-CoV-2 will continue to circulate in the human population: an opinion from the point of view of the virus-host relationship |pdf=|usr=}}
| |
| − | {{tp|p=32246886|t=2020. COVID-19 transmission through asymptomatic carriers is a challenge to containment |pdf=|usr=}}
| |
| − | {{tp|p=32371096|t=ä. SARS-CoV-2 was already spreading in France in late December 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32081636|t=ä. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges |pdf=|usr=}}
| |
| − | {{tp|p=32360230|t=2020. Global coronavirus disease 2019: What has daily cumulative index taught us?|pdf=|usr=}}
| |
| − | {{tp|p=32305587|t=ä. Can post-exposure prophylaxis for COVID-19 be considered as one of outbreak response strategies in long-term care hospitals?|pdf=|usr=}}
| |
| − | {{tp|p=32199877|t=2020. Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status |pdf=|usr=}}
| |
| − | {{tp|p=32226294|t=2020. Knowledge, attitudes, and practices towards COVID-19 among Chinese residents during the rapid rise period of the COVID-19 outbreak: a quick online cross-sectional survey |pdf=|usr=}}
| |
| − | {{tp|p=32370204|t=2020. How Big Data and Artificial Intelligence Can Help Better Manage the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32370069|t=2020. Alternative Global Health Security Indexes for Risk Analysis of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32244498|t=2020. Impact of the COVID-19 Pandemic on Mental Health and Quality of Life among Local Residents in Liaoning Province, China: A Cross-Sectional Study |pdf=|usr=}}
| |
| − | {{tp|p=32244425|t=2020. Prediction of Number of Cases of 2019 Novel Coronavirus (COVID-19) Using Social Media Search Index |pdf=|usr=}}
| |
| − | {{tp|p=32235413|t=2020. Response to the COVID-19 Epidemic: The Chinese Experience and Implications for Other Countries |pdf=|usr=}}
| |
| − | {{tp|p=32276501|t=2020. Spatio-Temporal Patterns of the 2019-nCoV Epidemic at the County Level in Hubei Province, China |pdf=|usr=}}
| |
| − | {{tp|p=32365851|t=2020. Combating the COVID-19 Epidemic: Experiences from Vietnam |pdf=|usr=}}
| |
| − |
| |
| | *'''[[Failure of politics and public health guidance]]''' | | *'''[[Failure of politics and public health guidance]]''' |
| | {{tp|p=32363133|t=ä. The Inadequacy of Regulatory Frameworks in Time of Crisis and in Low-Resource Settings: Personal Protective Equipment and COVID-19 |pdf=|usr=}} | | {{tp|p=32363133|t=ä. The Inadequacy of Regulatory Frameworks in Time of Crisis and in Low-Resource Settings: Personal Protective Equipment and COVID-19 |pdf=|usr=}} |
| Zeile 357: |
Zeile 157: |
| | *'''[[Failure of executive measures]]''' | | *'''[[Failure of executive measures]]''' |
| | *'''[[Political abuse of Covid19]]''' | | *'''[[Political abuse of Covid19]]''' |
| − | {{tp|p=C7152572|t=ä. Coronavirus Goes Viral: Quantifying the COVID-19 Misinformation Epidemic on Twitter |pdf=|usr=}}
| |
| − | {{tp|p=32241328|t=ä. Limited Early Warnings and Public Attention to Coronavirus Disease 2019 in China, January?February, 2020: A Longitudinal Cohort of Randomly Sampled Weibo Users |pdf=|usr=}}
| |
| − | {{tp|p=32332201|t=2020. Infodemic and the spread of fake news in the COVID-19-era |pdf=|usr=}}
| |
| − | {{tp|p=32268929|t=ä. Level of underreporting including underdiagnosis before the first peak of COVID-19 in various countries: Preliminary retrospective results based on wavelets and deterministic modeling |pdf=|usr=}}
| |
| − | {{tp|p=32363010|t=2020. Do the current cases reported to the WHO provide a realistic incidence rate of countries infected with COVID-19?|pdf=|usr=}}
| |
| − | {{tp|p=32235433|t=2020. Corona Virus (COVID-19) ?Infodemic? and Emerging Issues through a Data Lens: The Case of China |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Lost people]]''' | | *'''[[Lost people]]''' |
| Zeile 379: |
Zeile 172: |
| | *[[coviki state of development]] | | *[[coviki state of development]] |
| | *'''[[misc.]]''' | | *'''[[misc.]]''' |
| − | {{tp|p=32223767|t=ä. Unprecedented Solutions for Extraordinary Times: Helping Long-Term Care Settings Deal with the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32317510|t=2020. Why is SARS-CoV-2 testing not possible in every medical laboratory?|pdf=|usr=}}
| |
| − | {{tp|p=32367931|t=2020. Facial Pressure Ulcers in a COVID-19 50-year-old Female Intubated Patient |pdf=|usr=}}
| |
| − | {{tp|p=32284470|t=2020. COVID-19 and Indian Pediatrics(JOUR) |pdf=|usr=}}
| |
| − | {{tp|p=32297847|t=ä. COVID-19 affects healthy pediatricians more than pediatric patients |pdf=|usr=}}
| |
| − | {{tp|p=32289099|t=2020. IDM editorial statement on the 2019-nCoV |pdf=|usr=}}
| |
| − | {{tp|p=32216866|t=ä. COVID-19 positive test result from a private hospital laboratory: Neglecting to report and problems with national infection control |pdf=|usr=}}
| |
| − | {{tp|p=32226284|t=2020. The global battle against SARS-CoV-2 and COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32201354|t=ä. SARS-CoV-2: fear versus data |pdf=|usr=}}
| |
| − | {{tp|p=32321654|t=2020. The globe on the spotlight: Coronavirus disease 2019 (Covid-19) |pdf=|usr=}}
| |
| | {{tp|p=32319220|t=2020. Covid-19 and Namaste |pdf=|usr=}} | | {{tp|p=32319220|t=2020. Covid-19 and Namaste |pdf=|usr=}} |
| | *'''[[from the ads]]''' | | *'''[[from the ads]]''' |
